Prediction of Response to Hormone Therapy in Prostate Cancer by Bromodeoxyuridine Labeling
| Project/Area Number |
63570749
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
TAKEUCHI Masafumi Ehime University, School of Medicine, Urology, Proffessor, 医学部, 教授 (70028471)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ODA Hideaki Ehime University, School of Medicine, Urology, Assistant, 医学部, 助手 (20194558)
YOKOYAMA Masayoshi Ehime University, School of Medicine, Urology, Associated Professor, 医学部附属病院, 講師 (50116993)
吉岡 進 愛媛大学, 医学部, 助手 (10145097)
|
|---|
| Project Period (FY) |
1988 – 1990
|
| Project Status |
Completed (Fiscal Year 1990)
|
| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 1990: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1989: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1988: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | bromodeoxyuridine / prostate cancer, / bladder cancer / renal cancer / hormone therapy / chemotherapy / bromodeoxyuridine(BrdU) |
|---|
| Research Abstract |
It is very beneficial to predict the efficacy of medical treatments for cancer such as the hormone treatment for prostate cancer or the chemotherapy for bladder or renal cancer. The labeling index of bromodeoxyuridine (BrdU), which is a marker of DNA synthesis in cells, was measured both before and after the treatment in tissues of urological malignancies. For this purpose we developed a new device for labeling tissues with BrdU. The device, composed of a syringe and a container, made it possible to labeling the tissue in vitro easier and more promptly than before. Thirteen patients with prostate cancer, 10 with bladder cancer and 2 with renal cancer were examined. In all the prostate cancer patients, the labeling index was much decreased after the hormone treatment. Four patients showed the labeling indexes greater than 2 per cents although many of others showed no labeled cells. Three of the 4 patients encountered progression or early relapse of the disease. On the other hand, patients with no labeling cells had no recurrence or progression.
There were no significant findings on bladder cancer or renal cancer because the number of cases in this series was very limited.
|
Report
(4 results)
Research Products
(5 results)
